Xingping Yang

Xingping Yang

Auto-generated profile, based on publicly available information

Xingping Yang

Department of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HZhaosheng zheng
haosheng zheng
GLGuojie Long
Guojie Long
YZYuzhen Zheng
Yuzhen Zheng
XYXingping Yang
Xingping Yang
WCWeijie Cai
Weijie Cai
HLHong-Ying Liao
Hong-Ying Liao
SLC2A1 plays a pivotal role in cancer glycometabolism. SLC2A1 has been proposed as a putative driver gene in various cancers. However, a pan-cancer analysis of SLC2A1 has not yet been performed. In this study, we explored the expression and prognosis of SLC2A1 in pan-cancer across multiple databases. We conducted genetic alteration, epigenetic, and functional enrichment analyses of SLC2A. We calculated the correlation between SLC2A1 and tumor microenvironment using the TCGA pan-cancer dataset. We observed high expression levels of SLC2A1 with poor prognosis in most cancers. The overall genetic alteration frequency of SLC2A1 was 1.8% in pan-cancer, and the SLC2A1 promoter was hypomethylation in several cancers. Most m6A-methylation-related genes positively correlated with the expression of SLC2A1 in 33 TCGA cancers. Moreover, SLC2A1 was mainly related to the functions including epithelial–mesenchymal transition, glycolysis, hypoxia, cell-cycle regulation, and DNA repair. Finally, SLC2A1 positively associated with neutrophils and cancer-associated fibroblasts in the tumor microenvironment of most cancers and significantly correlated with TMB and MSI in various cancers. Notably, SLC2A1 was remarkably positively correlated with PD-L1 and CTLA4 in most cancers. SLC2A1 might serve as an attractive pan-cancer biomarker for providing new insights into cancer therapeutics.

4 February 2021 in Environmental Toxicology
Verified
Journal Article
Closed access
PDF file
YZYuzhen Zheng
Yuzhen Zheng
XYXingping Yang
Xingping Yang
JTJian Tan
Jian Tan
RTRenjiang Tian
Renjiang Tian
PSPiao Shen
Piao Shen
HLHong-Ying Liao
Hong-Ying Liao

18 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
HZhaosheng zheng
haosheng zheng
GLGuojie Long
Guojie Long
YZYuzhen Zheng
Yuzhen Zheng
XYXingping Yang
Xingping Yang
WCWeijie Cai
Weijie Cai
HLHong-Ying Liao
Hong-Ying Liao
The authors wish to make the following corrections to this paper

28 May 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
HLHong-Ying Liao
Hong-Ying Liao
XLXiaolong Luo
Xiaolong Luo
YHYisheng Huang
Yisheng Huang
XYXingping Yang
Xingping Yang
YZYuzhen Zheng
Yuzhen Zheng
XDXiaofang Deng
Xiaofang Deng
Purpose. DNA methylation heterogeneity is a type of tumor heterogeneity in the tumor microenvironment, but studies on the identification of the molecular heterogeneity of the lung adenocarcinoma genome with respect to DNA methylation sites and their roles in lung cancer progression and prognosis are scarce. Methods. Prognosis-associated DNA methylation subtypes were filtered by the Cox proportional hazards model and then established by unsupervised cluster analysis. Association analysis of these subtypes with clinical features and functional analysis of annotated genes potentially affected by methylation sites were performed. The robustness of the model was further tested by a Bayesian network classifier. Results. Over 7 thousand methylation sites were associated with lung adenocarcinoma prognosis. We identified seven molecular methylation subtypes, including 630 methylation sites. The subtypes yielded the most stable results for differentiating methylation profiles, prognosis, and gene expression patterns. The annotated genes potentially affected by these methylation sites are enriched in biological processes such as morphogenesis and cell adhesion, but their individual impact on the tumor microenvironment and prognosis is multifaceted. Discussion. We revealed that DNA methylation heterogeneity could be clustered and associated with the clinical features and prognosis of lung adenocarcinoma, which could lead to the development of a novel molecular tool for clinical evaluation.

21 February 2023 in Disease Markers
Verified
Journal Article
Open access
PDF file
JTJian Tan
Jian Tan
PSPiao Shen
Piao Shen
XYXingping Yang
Xingping Yang
WCWeijie Cai
Weijie Cai
HLHong-Ying Liao
Hong-Ying Liao
Objective. T cell immunoglobulin and mucin-containing protein-3 (TIM-3) is an important immune checkpoint, but its role in lung cancer is still not clear. In this study, we investigated TIM-3 protein expression and its correlation with TNF-α and IFN-γ by examining the tissues of patients with lung adenocarcinoma. Methods. We detected the mRNA quantity of TIM-3, TNF-α, and IFN-γ in 40 surgically resected specimens from patients with lung adenocarcinoma by real-time quantitative polymerase chain reaction (qRT-PCR). The protein expression of TIM-3, TNF-α, and IFN-γ was assessed in normal tissues, paracarcinoma tissues, and tumor tissues by western blotting, respectively. The relevance between the expression and clinicopathological information of the patients was analyzed. Results. The results showed that the expression level of TIM-3 was higher in tumor tissues than normal tissues and paracancerous tissues ( ). On the contrary, the expression of TNF-α and IFN-γ in tumor tissues was lower than normal tissues and paracarcinoma tissues ( ). However, the expression levels of IFN-γ mRNA were not observed to be significantly different between cancerous tissues and adjacent tissues. While TIM-3 protein expression in cancer tissues of patients with lymph node metastasis was higher than in patients without metastasis, the expression of TNF-α and IFN-γ was lower ( ). Importantly, the expression of TIM-3 was negatively correlated with the expression of TNF-α and IFN-γ, and the expression of TNF-α was found to be positively correlated with IFN-γ in the patient. Conclusion. The high expression of TIM-3, the low expression of TNF-α and IFN-γ, and the synergistic effect of TNF-α and IFN-γ in patients with lung adenocarcinoma were closely related to poor clinicopathological characteristics. Overexpression of TIM-3 may play an important role in the relationship between TNF-α and IFN-γ secretion and poor clinicopathological characteristics.